NASDAQ:FENC

Fennec Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy FENC

*Your capital is at risk

$9.14

-0.84 (-8.42%)

At Close: Jun 03, 2026

Fennec Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -80.27. In total, the insiders bought 1.25M and sold 1.49M FENC shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-80.27
● Buy	1.25M shares
● Sell	1.49M shares
79% Buy Activity Weak Negative Correlation
Buy Signal Low Confidence Mar 31, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -80.27. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (79% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Dec 05, 2025 Sell	Common shares S-Sale	Raykov Rosty Director	Director	10 000 Value: $75.4K
Dec 01, 2025 Buy	Common shares A-Award	Raykov Rosty Director	Director	5 208 Value: $40.3K
Dec 01, 2025 Buy	Common shares A-Award	Andrade Robert Chief Financial Officer	C-Suite Officer	2 430 Value: $18.8K
Nov 18, 2025 Sell	Common Stock S-Sale	Southpoint Capital Advisors Lp 10 Percent Owner	10% Owner	19 341 Value: $170.0K
Nov 17, 2025 Sell	Common Stock S-Sale	Southpoint Capital Advisors Lp 10 Percent Owner	10% Owner	85 918 Value: $755.2K
Nov 14, 2025 Sell	Common Stock S-Sale	Southpoint Capital Advisors Lp 10 Percent Owner	10% Owner	160 100 Value: $1.28M
Nov 05, 2025 Sell	Common shares S-Sale	Raykov Rosty Director	Director	10 000 Value: $81.0K
Oct 31, 2025 Buy	Common shares A-Award	Raykov Rosty Director	Director	5 208 Value: $42.7K
Oct 31, 2025 Buy	Common shares A-Award	Andrade Robert Chief Financial Officer	C-Suite Officer	2 430 Value: $19.9K
Oct 10, 2025 Sell	Common Shares S-Sale	Rallis Chris A Director	Director	1 775 Value: $16.4K
Oct 10, 2025 Buy	Common Shares M-Exempt	Rallis Chris A Director	Director	4 062 Value: $5K
Oct 10, 2025 Buy	Common Shares M-Exempt	Rallis Chris A Director	Director	4 062 Value: $5K
Oct 10, 2025 Sell	Common Shares S-Sale	Rallis Chris A Director	Director	1 775 Value: $16.4K
Oct 10, 2025 Buy	Common Shares M-Exempt	Rallis Chris A Director	Director	4 062 Value: $5K
Oct 10, 2025 Buy	Common Shares M-Exempt	Rallis Chris A Director	Director	4 062 Value: $5K
Oct 09, 2025 Sell	Common Stock S-Sale	Southpoint Capital Advisors Lp 10 Percent Owner	10% Owner	20 609 Value: $192.6K
Oct 09, 2025 Sell	Common Stock S-Sale	Southpoint Capital Advisors Lp 10 Percent Owner	10% Owner	20 609 Value: $192.6K
Oct 08, 2025 Sell	Common Stock S-Sale	Southpoint Capital Advisors Lp 10 Percent Owner	10% Owner	19 605 Value: $185.7K
Oct 08, 2025 Sell	Common Stock S-Sale	Southpoint Capital Advisors Lp 10 Percent Owner	10% Owner	19 605 Value: $185.7K
Oct 08, 2025 Buy	Stock Options M-Exempt	Raykov Rosty Director	Director	4 609 Value: $11.3K
Oct 08, 2025 Buy	Common shares M-Exempt	Raykov Rosty Director	Director	4 609 Value: $11.3K
Oct 08, 2025 Buy	Common shares M-Exempt	Raykov Rosty Director	Director	4 609 Value: $11.3K
Oct 08, 2025 Buy	Stock Options M-Exempt	Raykov Rosty Director	Director	4 609 Value: $11.3K
Oct 07, 2025 Sell	Common Stock S-Sale	Southpoint Capital Advisors Lp 10 Percent Owner	10% Owner	26 900 Value: $257.9K
Oct 07, 2025 Sell	Common Stock S-Sale	Southpoint Capital Advisors Lp 10 Percent Owner	10% Owner	26 900 Value: $257.9K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT FENNEC PHARMACEUTICALS, INC

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is ba...

Read Full Profile Here